BWX Technologies Secures Inaugural BBB Rating From Fitch

BWX Technologies, Inc. announced (BWXT ) on September 23, 2026 that it has received an inaugural investment grade credit rating of BBB with a Stable Outlook from Fitch Ratings. Fitch assigned the company’s revolving credit facility a BBB+ rating and its 4.125% senior notes due in 2028 and 2029 BBB ratings, the company said.

Fitch’s own rating action commentary, published from New York on September 23, 2026, records a BBB Long-Term Issuer Default Rating, a BBB+ rating on the senior secured revolver and a BBB rating on the senior unsecured notes, each listed as a New Rating. The date of the relevant rating committee was September 10, 2026.

“We are pleased to receive a BBB investment grade rating from Fitch, reflecting our critical role in providing nuclear solutions to national security and commercial power customers, strong financial position and disciplined approach to capital allocation,” said Mike Fitzgerald, BWXT’s chief financial officer. Fitzgerald said the rating reflects actions the company has taken to optimize its balance sheet while maintaining the financial flexibility to invest in its business and support long-term growth.

BWXT’s announcement said Fitch cited the company’s strong position in providing critical nuclear reactor components and fuel for U.S. naval propulsion and other strategic government programs, backed by specialized licenses, intellectual property and the ability to meet stringent regulatory requirements. The company said Fitch also cited multi-year revenue visibility and cash flow stability supported by its backlog, a conservative financial policy and the flexibility to fund growth initiatives while maintaining leverage consistent with an investment grade rating.

Fitch’s Rating Rationale

In its commentary, Fitch said BWXT holds an “effectively unrivaled sole-source position in North American nuclear reactor components and fuel,” with specialized licenses, intellectual property and stringent regulatory requirements creating high barriers to entry. It cited the U.S. Navy’s 30-year shipbuilding plan and procurement for the Ford-class aircraft carrier and Virginia- and Columbia-class submarines as underpinning a predictable revenue base and long-duration contracted cash flows, and put the company’s backlog at $8.4 billion, about 2.5 times revenue, with roughly 70% tied to mission-critical U.S. government-funded programs.

Fitch said around 70% of sales are tied to the U.S. government and that revenue of roughly $3.8 billion is modest relative to investment-grade aerospace and defense peers, with modest scale, concentrated exposure and execution risk from commercial expansion constraining the credit profile. It said the medical divestiture modestly reduces end-market diversification, while noting that entrenched positions in programs with durable bipartisan support have supported stable cash flow through cycles. The Precision Components Group and Kinectrics acquisitions position the company for growth in commercial reactors, services and small modular reactors, Fitch said, though expansion requires incremental investment and creates timing and utilization risk if customer commitments lag.

Fitch forecasts EBITDA margins around 18%, supported by fixed-price incentive contract structures with risk-sharing provisions that limit cost-overrun exposure, with near-term pressure expected from a greater mix of lower-margin commercial contracts and continued growth investment. In Fitch’s peer analysis, BWXT has smaller scale and higher margins but higher leverage than Huntington Ingalls, rated BBB with a Stable Outlook, and substantially smaller scale, narrower diversification and weaker credit metrics than Northrop Grumman (NOC ), rated BBB+ with a Positive Outlook.

Financial Policy, Liquidity and Rating Sensitivities

Fitch expects EBITDA leverage to be sustained around or below 3.0 times over the forecast horizon, consistent with the company’s stated target of 2.0 times to 3.0 times net leverage. It views BWXT’s capital allocation priorities as balanced across capital investment of around 6% of revenue, dividends of around 30% of pre-dividend free cash flow, acquisitions and debt reduction. Fitch projects annual post-dividend free cash flow of $100 million to $200 million, which, together with approximately $600 million of proceeds from the medical business divestiture, it said should provide flexibility to fund growth without materially increasing leverage.

Fitch expects capital expenditures of 6% to 7% of revenue, reflecting maintenance spending of around 4% plus expansion of special materials capacity, uranium enrichment capability and the U.S. commercial manufacturing footprint. It views liquidity as ample, citing $611 million of cash and cash equivalents and $1.25 billion of undrawn revolver capacity as of June 30, 2026. BWXT’s debt structure consists of senior unsecured notes, including a convertible note, and a senior secured revolving credit facility, with a maturity schedule Fitch described as well laddered and the nearest maturity in 2028.

Fitch said EBITDA leverage sustained above 3.0 times in conjunction with weaker financial flexibility, continued capital spending absent a visible order pipeline or customer commitments, or reduced U.S. government funding visibility or program delays could individually or collectively lead to a downgrade. A material increase in scale or diversification that reduces customer and program concentration, or EBITDA leverage sustained below 2.0 times, could individually or collectively lead to an upgrade.

BWXT reported second-quarter 2026 revenue of $901.6 million, up 18% from $764.0 million a year earlier, net income of $89.1 million and adjusted EBITDA of $155.5 million in results released August 3, 2026. Backlog stood at $8,398,081 thousand at June 30, 2026, comprising $6,797,627 thousand in Government Operations and $1,600,454 thousand in Commercial Operations, compared with $6,015,191 thousand a year earlier. The company’s balance sheet showed long-term debt of $2,019,897 thousand at June 30, 2026.

With those results, BWXT raised its 2026 guidance to revenue of approximately $3.8 billion, adjusted EBITDA of $662 million to $672 million, non-GAAP earnings per share of $4.70 to $4.80 and free cash flow of $345 million to $360 million, citing strong first-half performance and contribution from the Precision Components Group acquisition. Full-year 2025 revenue was $3,198 million. The company closed the Precision Components Group, LLC acquisition on July 1, 2026, announced the sale of its medical business and paid a quarterly dividend of $0.27 per common share, totaling $24.7 million, in the second quarter.

Fitch’s issuer profile describes BWXT as a designer and manufacturer of nuclear components, reactors and fuel that provides technologies and services for government and commercial applications.